MedTrace Logo

T-cell And General Immune Response to Seasonal Influenza Vaccine (SLVP018) - Year 1, 2009

NCT01987349 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 72

Last updated 2017-05-12

Study results available
· View outcomes & findings →

Summary

This study will compare influenza vaccine responses in monozygotic and dizygotic twins.

Conditions

Interventions

BIOLOGICAL

Fluzone® (intramuscular)

Licensed seasonal trivalent inactivated influenza vaccine (IIV3)

BIOLOGICAL

FluMist® (intranasal)

Licensed trivalent seasonal live attenuated influenza vaccine (LAIV3)

Sponsors & Collaborators

  • National Institute of Allergy and Infectious Diseases (NIAID)

    collaborator NIH

  • Stanford University

    lead OTHER

Principal Investigators

  • Cornelia L Dekker, MD · Stanford University

  • Mark M Davis, PhD · Stanford University

  • Garry Nolan, PhD · Stanford University

  • Ann Arvin, MD · Stanford University

  • Stephen Quake, PhD · Stanford University

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
8 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-09-30
Primary Completion
2010-01-31
Completion
2010-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01987349 on ClinicalTrials.gov